Sun Pharmaceutical Industries (Sun Pharma) said that one of its fully-owned subsidiaries has launched the generic version of Pfizer-developed Palbociclib in India for patients with advanced breast cancer. The Indian pharma company will make the anti-cancer drug available under the brand name PALENO (Palbociclib) 75 mg, 100 mg, and 125 mg. Palbociclib has approval in […]
Regeneron Pharmaceuticals has secured the approval of the Japanese Ministry of Health, Labor and Welfare (MHLW) to manufacture and market the company’s Libtayo (cemiplimab) for advanced or recurrent cervical cancer. Libtayo is a type of immunotherapy intended for the treatment of patients with advanced or recurrent cervical cancer whose disease progressed after chemotherapy. The approval […]
Ayala Pharmaceuticals, a Nasdaq-listed clinical-stage oncology company, has entered into a merger deal with New Jersey-based biotech company Advaxis. Based in Delaware, Ayala Pharmaceuticals is engaged in developing small molecule therapeutics for aggressive cancers and rare tumors. On the other hand, Advaxis is focused on developing immunotherapies based on a technology that makes use of […]
Aura Biosciences said that it has dosed the first patient in a phase 1 clinical trial of its first virus-like drug conjugate (VDC) — belzupacap sarotalocan for the treatment of non-muscle invasive bladder cancer (NMIBC). According to the NASDAQ-listed clinical-stage biotech company, the early-stage multi-center, open label study is likely to take in nearly 23 […]
Dr Reddy’s Laboratories said that it has launched two of six strengths of cancer medication Lenalidomide Capsules, a generic of Revlimid, which has been approved by the US Food and Drug Administration (FDA). The Indian pharma company is entitled to first-to-market, 180 days of generic drug exclusivity for the product in 2.5mg and 20mg strengths […]
Chinese biopharma company Innovent Biologics and French pharma giant Sanofi have entered into a partnership that aims to bring innovative drugs to patients in China suffering from difficult-to-treat cancers. The two parties plan to expedite the development and commercialization of a couple of important clinical stage oncology assets of Sanofi, which are SAR408701 (tusamitamab ravtansine; […]
Amgen has agreed to acquire ChemoCentryx, a biopharma company engaged in developing medications for inflammatory and autoimmune diseases and cancer, in an all-cash deal worth around $3.7 billion. Based in California, ChemoCentryx is listed on NASDAQ. As per the terms of the deal, its shareholders will be offered $52 per share. Through the deal, Amgen […]
HUTCHMED (China) has launched a phase 1 clinical trial of its oncology drug candidate HMPL-A83 in China in patients having advanced malignant neoplasms. HMPL-A83 is an investigational IgG4-type humanized anti-CD47 monoclonal antibody. The phase 1 clinical trial in China is a multicenter, open-label study, which will assess HMPL-A83’s safety, tolerability, pharmacokinetics, and preliminary efficacy in […]
Merck has signed a global development and commercialization deal worth $290 million with Orion Corporation for the latter’s investigational candidate ODM-208 and other drugs that target cytochrome P450 11A1 (CYP11A1). ODM-208, which is an oral, non-steroidal inhibitor of CYP11A1, is presently being assessed by the Finnish pharma company in a phase 2 clinical trial for […]
Prescient Therapeutics has secured the orphan drug designation for its PTX-100 compound from the US Food and Drug Administration (FDA) for the treatment of peripheral T-cell lymphomas (PTCL). According to the Australian oncology company, the FDA orphan drug designation will enable it in getting incentives that can help the development of PTX-100, which is a […]